Abstract
A newly developed new quinolone antimicrobial drug, pazufloxacin (PZFX), was clinically investigated, and the following results were obtained.
1) PZFX was administered to one patient with endometritis and five with external genital infection, and the drug was effective in all six patients.
2) Seven strains of bacteria were isolated from the six patients, and all the strains were eradicated bacteriologically by the treatment. One case of Corynebacterium sp. was replaced.
3) No abnormal changes in clinical laboratory findings or side effects were observed in any of the patients.
